Important Information for ESSA Pharma Inc. (EPIX) Investors: Rosen Law Firm Reminds of Class Action Lawsuit Deadline
NEW YORK, March 06, 2025 – Rosen Law Firm, a global investor rights law firm, alerts purchasers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline in a securities class action. This Class Action seeks to recover damages on behalf of ESSA Pharma investors under the federal securities laws.
Background on ESSA Pharma
ESSA Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of rare and debilitating diseases. The company’s lead product candidate, EPI-5895, is a potassium channel activator being developed for the treatment of primary hyperkalemia, a condition characterized by high levels of potassium in the blood. EPI-5895 has completed a Phase 2b proof-of-concept study and is currently in a pivotal Phase 3 clinical trial.
The Class Action Allegations
The complaint alleges that during the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational, and financial metrics. Specifically, the defendants misrepresented the clinical development and commercial potential of EPI-5895, failing to disclose material information about the drug’s safety concerns and clinical trial results.
Impact on ESSA Pharma Investors
As a result of this alleged misconduct, ESSA Pharma investors suffered significant losses. On October 31, 2024, the Company announced that the primary endpoint of the pivotal Phase 3 clinical trial for EPI-5895 was not met, causing the stock price to drop significantly. Investors who purchased ESSA Pharma securities during the Class Period may be entitled to recover their losses.
Impact on the World
The failure of EPI-5895 in its clinical trial is a setback for the pharmaceutical industry as a whole. It highlights the importance of transparency in clinical trial results and the risks associated with investing in biopharmaceutical companies, particularly those in the late-stage clinical trial phase. This incident serves as a reminder for investors to carefully consider the potential risks and rewards before investing in any securities.
Conclusion
If you purchased ESSA Pharma securities during the Class Period, you may be entitled to recover your losses. The lead plaintiff deadline is March 25, 2025. Rosen Law Firm encourages investors to contact the firm to discuss their potential recovery options. This notice does not constitute an offer or solicitation to sell or purchase securities, nor does it constitute legal advice. For more information, please contact Phillip Kim or Kevin Chan of Rosen Law Firm at 212-686-1060 or [email protected] or [email protected].
- ESSA Pharma Inc. (NASDAQ: EPIX)
- Class Period: December 12, 2023 to October 31, 2024
- Lead Plaintiff Deadline: March 25, 2025
- Securities Class Action
- Rosen Law Firm
